retatrutide benefits clinical trial retatrutide Eli Lilly's shows promising weight loss results in phase 3 Retatrutide for weight loss: Study

H.BlochO.Zelnic-YuvalD.LoveI.Mendel-CohenL.FlorH.et al (2018)

Lillys triple agonist retatrutide delivered weight loss of up to an average of 71.2 lbs in first successful Phase 3 trial. Retrieved 2026-07-03

Still, home readings and in-office readings can vary

The decision to continue or modify GLP-1 treatment should be made collaboratively, weighing the benefits of metabolic control against the distress caused by hair loss

The weight loss peptide landscape is evolving rapidly with several promising compounds in advanced clinical development

Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs